Karen L. Smith - 16 May 2022 Form 4 Insider Report for Talaris Therapeutics, Inc. (TRML)

Role
Director
Signature
/s/ Mary Kay Fenton, as Attorney-in-Fact
Issuer symbol
TRML
Transactions as of
16 May 2022
Net transactions value
$0
Form type
4
Filing time
17 May 2022, 18:15:23 UTC
Previous filing
01 Mar 2022
Next filing
23 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TALS Stock Option (Right to Buy) Award $0 +29,002 $0.000000 29,002 16 May 2022 Common Stock 29,002 $6.54 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option shall vest in three equal installments from the date of grant.